Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
Geert D’Haens(Amsterdam University Medical Centers), Remo Panaccione(University of Calgary), Filip Baert(AZ Delta), Peter Bossuyt(Imelda Hospital), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Silvio Danese(Vita-Salute San Raffaele University), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Brian G. Feagan(Western University), Tadakazu Hisamatsu(Kyorin University), Allen Lim(University of Alberta), James O. Lindsay(Queen Mary University of London), Edward V. Loftus(Mayo Clinic), Julián Panés(Centro de Investigación Biomédica en Red), Laurent Peyrin‐Biroulet(Inserm), Zhihua Ran(Shanghai Jiao Tong University), David T. Rubin(University of Chicago), William J. Sandborn(University of California San Diego), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Ezequiel Neimark(AbbVie (United States)), Alexandra Song(AbbVie (United States)), Kristina Kligys(AbbVie (United States)), Yinuo Pang(AbbVie (United States)), Valerie Pivorunas(AbbVie (United States)), Sofie Berg(AbbVie (United States)), W. Rachel Duan(AbbVie (United States)), Bidan Huang(AbbVie (United States)), Jasmina Kalabic(AbbVie (Germany)), Xiaomei Liao(AbbVie (United States)), Anne Robinson(AbbVie (United States)), Kori Wallace(AbbVie (United States)), Marc Ferrante(KU Leuven)
Cited by 378Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis